IFP Advisors Inc Boosts Position in IDEXX Laboratories, Inc. (IDXX)

IFP Advisors Inc increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 134.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 937 shares of the company’s stock after purchasing an additional 537 shares during the quarter. IFP Advisors Inc’s holdings in IDEXX Laboratories were worth $234,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Allianz Asset Management GmbH lifted its position in IDEXX Laboratories by 11.9% during the first quarter. Allianz Asset Management GmbH now owns 81,713 shares of the company’s stock valued at $15,639,000 after purchasing an additional 8,664 shares in the last quarter. IFM Investors Pty Ltd lifted its position in IDEXX Laboratories by 50.0% during the second quarter. IFM Investors Pty Ltd now owns 3,871 shares of the company’s stock valued at $844,000 after purchasing an additional 1,291 shares in the last quarter. State of Alaska Department of Revenue lifted its position in IDEXX Laboratories by 21.8% during the second quarter. State of Alaska Department of Revenue now owns 19,335 shares of the company’s stock valued at $4,213,000 after purchasing an additional 3,460 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new position in IDEXX Laboratories during the second quarter valued at $888,000. Finally, Daiwa SB Investments Ltd. lifted its position in IDEXX Laboratories by 21.9% during the second quarter. Daiwa SB Investments Ltd. now owns 4,390 shares of the company’s stock valued at $957,000 after purchasing an additional 790 shares in the last quarter. Institutional investors and hedge funds own 91.27% of the company’s stock.

Shares of IDEXX Laboratories stock opened at $209.67 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $146.09 and a 52 week high of $256.22. The stock has a market capitalization of $17.44 billion, a PE ratio of 49.82, a price-to-earnings-growth ratio of 2.57 and a beta of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, November 1st. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a negative return on equity of 994.76% and a net margin of 15.19%. The business had revenue of $545.00 million for the quarter, compared to the consensus estimate of $545.66 million. During the same period in the previous year, the business earned $0.76 earnings per share. The business’s revenue was up 10.8% on a year-over-year basis. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.19 EPS for the current fiscal year.

IDXX has been the topic of several analyst reports. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $274.00 target price on the stock in a research report on Thursday, August 2nd. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Canaccord Genuity lowered their target price on IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday. Bank of America lowered their target price on IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, November 2nd. Finally, Credit Suisse Group boosted their price objective on IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a research report on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $252.33.

In related news, insider Michael Lane sold 5,912 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $243.78, for a total value of $1,441,227.36. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jonathan W. Ayers sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $243.20, for a total value of $1,702,400.00. The disclosure for this sale can be found here. Insiders sold 64,844 shares of company stock worth $15,742,129 over the last 90 days. Company insiders own 2.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/09/ifp-advisors-inc-boosts-position-in-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: Tariff

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply